A 72-year-old man with CKD stage 3b (eGFR 38 mL/min/1.73 m²), albuminuria, and type 2 diabetes is reviewed. According to KDIGO 2024 CKD guidelines, which class of medication in addition to ACE inhibitor and SGLT2 inhibitor is recommended to further reduce progression and cardiovascular risk in appropriate patients?